We scan new podcasts and send you the top 5 insights daily.
When Bristol's LPA1 inhibitor hit statistical significance only at the low dose, it cast doubt on competitor claims that greater receptor coverage drives superior efficacy. In high-risk diseases like IPF, an ambiguous or flat dose-response curve introduces acute skepticism around translatability and commercial upside.
While companies fear losing to competitors, a bigger deterrent for head-to-head trials is the absence of a clear regulatory pathway to use favorable data (e.g., faster onset) for label claims. This removes a key commercial incentive for running these informative but risky studies.
Biogen's anti-tau ASO trial missed its primary endpoint because the lowest dose performed best—a biologically counterintuitive 'inverse dose-response.' This result challenges the drug's fundamental mechanism of action, as more drug should theoretically lead to better effect, creating a high bar for convincing regulators and investors of its viability.
With multiple PD-L1/VEGF bispecifics showing similar high efficacy, the ultimate market leader will likely be determined by strategic clinical trial design—including patient selection, endpoint ambition, and generation of robust global data—rather than minor molecular differences between the compounds.
The primary hurdle in drug development is the Phase 2 trial, where the most frequent cause of failure is a simple lack of efficacy. It is not typically due to safety concerns, business case changes, or target engagement issues, but rather that the drug produces no therapeutic effect upon administration.
For diseases like Idiopathic Pulmonary Fibrosis (IPF), existing treatments have such severe side effects that over half of patients refuse them. MannKind's strategy with its inhaled Nintendanib is based on the insight that physicians will prioritize a drug that patients can actually tolerate, even if it offers slightly less efficacy.
The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.
Despite lacking a placebo group, the stark difference in outcomes between uniQure's high-dose and low-dose cohorts offers a strong signal of the drug's effect. The high-dose group showed a 75% slowing of progression, a compelling piece of evidence the FDA appears to be discounting.
Ron Cooper highlights a key disconnect: Wall Street values the highest efficacy ("more is better"), but community physicians, who treat most patients, weigh three factors equally: efficacy, tolerability, and ease of administration. A drug that seamlessly integrates into their practice flow can win significant market share without best-in-class efficacy.
In rare diseases, a previously approved drug with modest results can lower the efficacy benchmark for newcomers. Palvella Therapeutics' drug for a rare skin disease may only need ~30% efficacy for approval, as a competitor's drug (Hiftor) was approved with just a 23% patient responder rate, creating a low bar for a clinical win.
When selecting an ADC dose for pivotal trials, the highest response rate is not the sole driver. Developers prioritize the best balance of efficacy and toxicity, often choosing a dose with slightly lower response but significantly fewer serious adverse events, discontinuations, and specific risks like ILD.